The UK and US have concluded a key trade agreement that will keep no levies on British drug products being sold in the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has committed to raise expenditure on drugs through the National Health Service (NHS). This move secures that import taxes on these crucial goods will stay at nothing for a duration of 36 months.
This agreement is in response to recent threats to hike duties on patented drug products, with potential rates mentioned as high as double the cost.
"This arrangement between the UK strengthens the international landscape for cutting-edge drugs and establishes much-needed fairness to transatlantic drug exports," a release noted.
Trade Importance
Pharmaceuticals are one of the the United Kingdom's biggest export categories to the United States, which is easily the largest destination for large companies like GSK and AstraZeneca.
Trade data show that in the year to the end of September, the UK sold pharmaceutical products valued at billions to the US. This figure accounted for 17.4% of British export trade in that timeframe.
"This guarantee safeguards employment, stimulates funding and facilitates the UK to emerge as a international leader for life sciences," a government official commented.
Specific NHS Changes
The pact involves several key pledges from the UK:
- Price Threshold Increase: The UK will lift the affordability limit at which it considers new medicines to be unaffordable by a quarter.
- Higher Drug Budget: There is a aim to raise overall NHS spending on drugs from 0.3 percent of GDP to 0.6% over the next decade.
- Refund Ceiling: The amount pharmaceutical firms must return to the NHS to control costs will be limited at 15%. In the past, refunds were more than 20%.
Broader Context
The pact takes place against a protracted tension between the sector and the UK government over spending levels and NHS adoption.
The disagreement were heightened by assertions that US customers were paying significantly more for the same drugs than patients in the UK and Europe.
Recently, several large manufacturing plans in the UK have been delayed or abandoned, while multi-billion-dollar investments have been directed toward US facilities.
A senior figure stated that the NHS needed to increase expenditure on medicines, noting that its spending on drugs had decreased as a percentage of its resources over the previous ten-year period.
